comparemela.com

Latest Breaking News On - Biopharma dive - Page 13 : comparemela.com

Gene editing startup Metagenomi files for an IPO

BioPharma

United statesArrivent biopharmaNovo holdingsUniversity of californiaNovo nordiskIonis pharmaceuticalsDive briefBiopharma diveCatalio capital management

Back On Track: Biopharmaceutical Sector Sees M&A Revival

Big Pharma’s balance sheets are strong and well-positioned for M&A activity.

Provention bioDmitry reykhartMerck keytrudaAbbvie humiraEli lillyBristol myers squibb eliquisNovarti entrestoNovo nordiskForbes finance councilGoldman sachs researchRuthenium global pharma fund board of directorsBellus healthRuthenium global pharma fund boardInflation reduction actBig pharmaBristol myers squibb

Bristol Myers to acquire brain drug developer Karuna for $14B

BioPharma

Ken rhodesBristol myersSteven paulEli lillyChristopher boernerBristol myerPuretech healthBristol myers squibbDrug administrationKaruna therapeuticsBiopharma diveCerevel therapeutics

Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn

BioPharma

United statesSan franciscoUnited kingdomRob hopfnerEli lillyPeter bisgaardPivotal life sciencesDive briefKaruna therapeuticsBiopharma diveBioluminescence ventures

Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air – Indianapolis Business Journal

Results of a clinical trial for Point Biopharma's lead compound fell short of analysts' expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.

William blairEli lillySan biotechnology value fundPoint biopharmaIndianapolis based point biopharmaBiopharma diveFierce biotechSan francisco based biotechnology value fund

vimarsana © 2020. All Rights Reserved.